Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
Complete cure and adverse events for terbinafine showed no clear difference in adverse events attributed to the study drugs compared with griseofulvin (moderate certainty).
It is very uncertain whether the intervention changes number of serious adverse events ‐ pulmonary (very low certainty).
CHLORPROMAZINE showed no clear difference in adverse events ‐ toxic reaction (short term) compared with RESERPINE (moderate certainty).
It is very uncertain whether bordered polyurethane changes adverse events assessed during catheter dwell compared with standard polyurethane (very low certainty).
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events at 12 weeks compared with four‐food elimination diet (very low certainty).
Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).
Pharmaceutical interventions showed no clear difference in adverse events: 1. death: at end of treatment compared with placebo (moderate certainty).
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).